ClinicalTrials.gg
Not yet recruitingNCT07625449LD-IVHUpdated Sep 4, 2026

Early Lumbar Drainage for Intraventricular Hemorrhage

An interventional study of Control treatment plus lumbar drainage and Control treatment schedule in Intraventricular Hemorrhage and Cerebral Hemorrhage, sponsored by Second Affiliated Hospital of Nanchang University. Not yet recruiting at 31 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Second Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.

Planned enrollment
25th of 77
392 · median 180
Started
2026
with 14 others
No phase
35 of 123
22 open now
Primary completion
2029-10
later than 53 of 61 live
Registered
113th of 123
by date

Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 25th largest by planned enrollment of the 77 interventional ones that give a count, is one of 15 that started in 2026, is one of 35 with no phase, reaches primary completion later than 53 of the 61 other live ones, and was the 113th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 114 Cerebral Hemorrhage studies recruiting now, 60 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Cerebral Hemorrhage with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial in Chinese patients with intraventricular hemorrhage (IVH), comparing early lumbar drainage added to standard care with standard care alone. The primary objective is to evaluate whether, in patients treated with external ventricular drainage (EVD) and intrathecal urokinase, the addition of early lumbar drainage improves functional outcomes at 180 days, as measured by the modified Rankin Scale (mRS), and reduces complications.

Read the detailed description

Intraventricular hemorrhage (IVH) is a life-threatening complication of acute stroke, associated with high rates of mortality and severe disability, fewer than 20% of survivors achieve favorable functional outcomes. Despite the widespread use of external ventricular drainage (EVD) and intraventricular thrombolysis, the role of early lumbar drainage in improving outcomes remains controversial, with limited high-level evidence from randomized controlled trials.

The LD-IVH study will use a 1:1 stratified block randomization design, with stratification by intraparenchymal hematoma and hospital. Eligible patients will be randomized to receive either (1) control group treatment: standard EVD plus daily intrathecal urokinase (30,000 IU) for 3 consecutive days, with a maximum treatment duration of 5 days; or (2) intervention group treatment: the same EVD and intrathecal urokinase regimen as the control group, with early lumbar drainage additionally initiated within 72 hours of onset. CSF was drained at a rate of ≤8 mL/h, with a daily maximum volume of 200 mL, to keep intracranial pressure stable.

The primary endpoint will be the proportion of patients with a favorable functional outcome (modified Rankin Scale [mRS] score 0-3) at 180 days. A total of 392 patients will be enrolled, and an interim efficacy analysis is planned after 50% of participants complete the 180-day follow-up.

03

Conditions studied

  • Intraventricular Hemorrhage
  • Cerebral Hemorrhage

Browse trials for

Keywords

  • Intraventricular Hemorrhage
  • Lumbar Drainage
  • External Ventricular Drainage
  • Urokinase
  • PROBE design
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-85 years, of either sex.
  2. First-ever intracerebral hemorrhage (ICH) with CT-confirmed hemorrhage involving the third and/or fourth ventricle, and scheduled to undergo or already having undergone burr-hole ventricular drainage.
  3. Intraparenchymal hemorrhage volume \<30 mL on admission CT, with stable neurological status and no progressive deterioration before randomization.
  4. Randomization completed within 72 hours of symptom onset.
  5. Pre-onset modified Rankin Scale (mRS) score of 0 (no symptoms) or 1 (minor symptoms not interfering with daily activities).
  6. Written obtained from the participant or a legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Secondary intracerebral hemorrhage, including imaging-confirmed untreated intracranial arteriovenous malformation (AVM), ruptured intracranial aneurysm, moyamoya disease, or intracranial tumor.
  2. Long-term use of anticoagulant medication, persistent coagulopathy, or known allergy to urokinase.
  3. (PT) or activated partial thromboplastin time (APTT) prolonged to more than twice the .
  4. Absolute to lumbar or external ventricular drainage (e.g., cerebral herniation, infection at the puncture site).
  5. Infratentorial hemorrhage with a volume ≥10 mL.
  6. Thalamic hemorrhage with a volume ≥10 mL, or accompanied by obvious extension into the midbrain, oculomotor nerve palsy, or fixed and dilated non-reactive pupils.
  7. Unilateral limb paralysis (muscle strength grade 0 or 1) before randomization.
  8. Active bleeding from other sites, including the gastrointestinal, genitourinary, or respiratory tracts.
  9. Multiple superficial ecchymoses, purpura, or other signs suggesting bleeding or a bleeding tendency.
  10. Expected survival of less than 6 months due to other causes.
  11. Other coexisting severe diseases that are difficult to treat.
  12. Pregnancy.
  13. Participation in another interventional clinical trial within 30 days before randomization.
  14. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
392 participants (estimated)

Study arms

  • Active comparator
    Control Group (EVD + Intrathecal Urokinase)

    Patients received external ventricular drainage (EVD) combined with intrathecal urokinase injection. Urokinase was administered as a single daily dose of 30,000 IU for 3 consecutive days. A follow-up cranial CT was then performed to assess ventricular obstruction and hematoma clearance, which guided the decision on whether to continue thrombolysis. The maximum total duration of urokinase treatment did not exceed 5 days. Thrombolysis was discontinued when CT demonstrated clearance of the third/fourth ventricular cast, relief of mass effect, or a hematoma clearance rate of ≥80%.

    Procedure: Control treatment schedule

  • Experimental
    Intervention Group (Control Treatment + Lumbar Drainage)

    In addition to the same EVD and intrathecal urokinase regimen as the control group, early lumbar drainage was initiated within 72 hours of onset. The CSF drainage rate was maintained below 8 mL/h, and the daily total drainage volume did not exceed 200 mL to maintain stable intracranial pressure.

    Procedure: Control treatment plus lumbar drainage

Interventions

  • ProcedureControl treatment plus lumbar drainage

    Early lumbar cistern drainage was initiated within 72 hours of onset. The CSF drainage rate was maintained below 8 mL/h, and the daily total drainage volume did not exceed 200 mL to maintain stable intracranial pressure.

  • ProcedureControl treatment schedule

    Patients receive external ventricular drainage (EVD) combined with intrathecal urokinase injection. Urokinase is administered as a single daily dose of 30,000 IU for 3 consecutive days, and the maximum duration of urokinase treatment does not exceed 5 days. Thrombolysis is discontinued when cranial CT demonstrates clearance of the third/fourth ventricular cast, relief of mass effect, or a hematoma clearance rate of ≥80%.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with mRS score 0-3 at 180 days after onset

    Percentage of patients with modified Rankin Scale score 0 to 3 at 180-day follow-up.

    Time frame: 180 days after disease onset

Secondary outcomes

  1. Proportion of participants with mRS 0-3 at 90 days after onset

    Percentage of patients with a modified Rankin Scale score of 0 to 3 at the 90-day follow-up.

    Time frame: 90 days after onset

  2. Proportion of participants with GOS score 4-5 at 180 days after onset

    Percentage of patients with a Glasgow Outcome Scale (GOS) score of 4 or 5 at the 180-day follow-up.

    Time frame: 180 days after onset

  3. Proportion of participants with mRS 0-2 at 90 days and 180 days

    Percentage of patients with a modified Rankin Scale score of 0 to 2 at the 90- and 180-day follow-up.

    Time frame: 90 and 180 days after disease onset

  4. Change in ordinal mRS score from baseline to 180 days after onset

    Change in the ordinal modified Rankin Scale score between baseline and the 180-day follow-up.

    Time frame: Baseline to 180 days after disease onset

  5. EQ-5D score at 180 days after onset

    Health-related quality of life measured by the EuroQol-5D (EQ-5D) questionnaire at the 180-day follow-up.

    Time frame: 180 days after disease onset

  6. Proportion of participants with Barthel Index score 75-100 at 180 days after onset

    Percentage of patients with a Barthel Index score of 75 to 100 at the 180-day follow-up.

    Time frame: 180 days after disease onset

  7. Proportion of participants with shunt-dependent hydrocephalus before discharge and at 180 days after onset

    Percentage of patients requiring permanent cerebrospinal fluid shunting for hydrocephalus before hospital discharge and at the 180-day follow-up.

    Time frame: Before hospital discharge and 180 days after disease onset

  8. Daily CSF drainage volume before catheter removal

    Daily volume of cerebrospinal fluid drained (mL/day) from the external ventricular drain and lumbar drain before removal of the drainage catheters.

    Time frame: During the drainage period before catheter removal

  9. Proportion of participants with resolution of third and/or fourth ventricular obstruction

    Percentage of patients with resolution of third and/or fourth ventricular obstruction on cranial CT within 14 days after enrollment or before hospital discharge.

    Time frame: Within 14 days after enrollment or before hospital discharge

  10. Dynamic intracranial hemorrhage clearance rate before catheter removal

    Serial (dynamic) rate of intracranial hemorrhage clearance on cranial CT before removal of the external ventricular and lumbar drainage catheters.

    Time frame: Before removal of the external ventricular and lumbar drainage catheters

  11. Length of hospital stay

    Total duration of hospitalization (days).

    Time frame: From admission to hospital discharge

  12. Length of NICU stay

    Total duration of stay in the intensive care unit (days).

    Time frame: From NICU admission to NICU discharge

  13. Total hospitalization costs

    Total medical costs incurred during hospitalization, in RMB.

    Time frame: From admission to hospital discharge

Other outcomes

  1. All-cause mortality at 180 days after onset

    Percentage of patients who died from any cause by the 180-day follow-up.

    Time frame: 180 days after disease onset

  2. Proportion of participants with intracranial infection

    Percentage of patients who developed intracranial infection during the study period.

    Time frame: From enrollment through hospital discharge

  3. Proportion of participants with cerebral herniation

    Percentage of patients who developed cerebral herniation.

    Time frame: From enrollment through hospital discharge

  4. Proportion of participants with symptomatic rebleeding within 72 hours after catheter placement or thrombolysis

    Percentage of patients with symptomatic intracranial rebleeding within 72 hours after catheter placement or intrathecal thrombolysis.

    Time frame: Within 72 hours after catheter placement or thrombolysis

  5. Proportion of participants with other serious adverse events

    Percentage of patients who experienced other serious adverse events during the study period.

    Time frame: From enrollment through the 180-day follow-up

07

Study locations

31 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.

Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 36 months is close to that.

Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2026
First posted
Jun 4, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07625449
Lead sponsor
Second Affiliated Hospital of Nanchang University
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Sep 4, 2026

Study contacts

Ping Hu, MD
Contact
hp666edu@163.com
+86 13097286794
Shigang Lv, MD
principal investigator · Second Affiliated Hospital of Nanchang University
Miaojing Wu, MD
principal investigator · Second Affiliated Hospital of Nanchang University
Zeguang Ren, Prof
principal investigator · Methodist Houston Sugar Land Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion